|Synonyms||Glybenclamide, Glyburide (USAN), HB-419, U-26452|
|Brand names||Daonil, DiaBeta, Glimel, Glynase|
Glibenclamide is a second-generation sulfonylurea (SGS), that is purported to have a higher potential for inducing hypoglycaemia than other SGSs because of its long half-life and is used primarily in the treatment of type 2 diabetes mellitus, although clinical experience does exist with its use in the treatment of permanent neonatal diabetes mellitus (PNDM) caused by defects in the genes encoding the ATP-sensitive potassium channel and its components. It is also older than most other SGS agents.
- NCBI Bookshelf provides free book resources on this topic.
- PubMed provides review articles from the past five years (limit to free review articles or to systematic reviews)
- The TRIP database provides clinical publications about evidence-based medicine.
- ↑ Brayfield, A, ed. (16 September 2013). "Sulfonylureas Antidiabetics". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 1 October 2014.
- ↑ Pearson, ER; Flechtner, I; Njølstad, PR; Malecki, MT; Flanagan, SE; Larkin, B; Ashcroft, FM; Klimes, I; Codner, E; Iotova, V; Slingerland, AS; Shield, J; Robert, JJ; Holst, JJ; Clark, PM; Ellard, S; Søvik, O; Polak, M; Hattersley, AT; Neonatal Diabetes International Collaborative Group (August 2006). "Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.". The New England Journal of Medicine 355 (5): 467–77. PMID 16885550. doi:10.1056/NEJMoa061759.
- ↑ "Second Generation Sulfonylureas". LiverTox. Bethesda, USA: U.S. National Library of Medicine. 10 September 2014. Retrieved 1 October 2014.